The Future of Companion Diagnostics
The Future of Companion Diagnostics
Publish Date: 2026-03-25 06:21:00
Source Domain: www.technologynetworks.com
As the companion diagnostics (CDx) field advances beyond its origins in single‑biomarker oncology tests, it is transforming into a sophisticated, multi-layered discipline that integrates genomics, proteomics, metabolomics, and powerful computational tools to guide therapeutic decisions with unprecedented accuracy.
Technology Networks recently spoke with Dr. Madhuri Hegde, chief scientific officer at Revvity, to explore the changing landscape of CDx, the technologies accelerating its progress, and the challenges researchers still face as diagnostics become increasingly data‑rich and clinically essential.
In this interview, Hegde also explores the value CDx brings to patients, healthcare systems, and the drug development process, and shares her perspective on what’s next as these tools expand beyond oncology into a wider range of diseases.
Senior Science Editor
Technology Networks
Anna is a senior science editor at Technology Networks. She holds a first-class honors degree in biological sciences from the University of East Anglia. Before joining Technology Networks she helped organize scientific conferences.
Can you give us an overview of CDx today and highlight some of the recent advances in this space?
